Daniel M. Bradbury. Mr. Bradbury is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm in La Jolla, California and formerly, the President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. Mr. Bradbury has nearly 30 years of pharmaceutical industry experience. During his 18-year tenure at Amylin, the company launched three first-in-class medicines: Symlin, Byetta and Bydureon. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb in August 2012. Before joining Amylin, Mr. Bradbury held marketing and sales positions for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury currently serves on the board of directors of Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Illumina, Inc. (NASDAQ: ILMN), BioMed Realty (NYSE: BMR), Biocon Limited (NSE: BIOCON), Castle Biosciences, Inc. (Private), DiaVacs (Private), Microdermis, Inc. (Private) and Profil Institute for Clinical Research (Private). He also serves on the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management’s Advisory Council and the University of Miami’s Innovation Corporate Advisory Council. Mr. Bradbury received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
David L. Snitman, Ph.D. Dr. Snitman is currently a principal at DL SNITMAN LLC, a consulting firm providing business development services to the biotechnology industry. Dr. Snitman is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015. While at Array, he was responsible for negotiation numerous deals with major pharmaceutical companies including Eli Lilly, AstraZeneca, Celgene to name a few. He was a member of Array’s Board of Directors from May 1998 to October 2012. Prior to forming Array, Dr. Snitman held senior positions with Amgen Inc. including Associate Director, New Products and Technology, and Manager of Amgen’s Boulder research facility. Dr. Snitman received a B.S. in chemistry from Northeastern University and obtained a Ph.D. in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology.